In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...

But now, in a surprise twist, the team that earned the Nobel Prize in chemistry for developing CRISPR is asking to cancel two ...

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...

If you love investing in stocks you're bound to buy some losers. Long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders ...

Two Nobel Prize winners want to cancel their own CRISPR patents in Europe In the decade-long fight to control CRISPR, the ...

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.92, marking a -1.86% move from the previous day.

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

CRISPR, the gene-editing technology, has been one of the major breakthroughs in biology in the last two decades. And while ...

Hypothetically, if you controlled which DNA is stored in the CRISPR regions, you could manipulate the bacteria into inserting ...

A Shift In The Geomagnetic Field Has Distorted Measurements Of The Florida Current Kamala Harris Turns Biden's $493 Billion ...